The field medicine and oncology through the past few decades experienced massive changes in term of innovations and inventions. Companies like Seattle Genetics lead in this, and it plays an undeniable role in providing options drug research and development. Through a commitment to designing and producing not only effective but also safe drugs, the founder Clay Siegall guides the company in achieving its success.
Cancer within the years remains a nightmare for many families and providers of health care service. Thus, as a responsibility given by the people, the government and most research institutions put a lot of effort in curbing the pandemic. Following suit is Seattle Genetic; the organization commits its intellectual capability, time and money to tirelessly finding a solution.
Though many challenges come, they eventually come out with success; they already developed the antibody-drug conjugate. In the field of oncology, it’s a pioneer drug. To ensure that they give back to the community appropriate partnership with other players in the industry got formed to provide mass production. GlaxoSmithKline and GeneTech are but an example of the organization.
It’s right to say that the founder Clay Siegall play an irreplaceable role in fostering exceptional leadership within Seattle Genetics. As a board of director Ultragenyx, his excellent managerial skills extend to the development of this company. Intellectually, also he accomplished a lot through the past few years, with some 70 publications written in his name and the patent, over 15 of them, certified in his name.
He graduated from Maryland University and Washington University with a remarkable bachelor degree in zoology and PhD in genetics respectively from the two institutions. Within the industry, he is a notable figure proven by his membership in two prestigious scientific organizations. First includes the Washington Roundtable and then the Biopharmaceutical. Currently, Clay is the president and CEO of Seattle Genetics.